
-
Inozyme Pharma NasdaqGS:INZY Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Location: 321 Summer Street, Boston, MA, 02210, United States | Website: https://www.inozyme.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
217.2M
Cash
84.78M
Avg Qtr Burn
-24.13M
Short % of Float
12.70%
Insider Ownership
1.23%
Institutional Own.
93.16%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease | Phase 3 Data readout | |
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease, ABCC6 Deficiency | Phase 1/2 Update | |
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease | Phase 1b Data readout | |
INZ-701 (ENPP1-Fc) Details End-stage renal disease | Phase 1 Data readout |